NO970385L - Analogifremgangsmåte for fremstilling av et terapautisk aktivt nukleosid - Google Patents

Analogifremgangsmåte for fremstilling av et terapautisk aktivt nukleosid

Info

Publication number
NO970385L
NO970385L NO970385A NO970385A NO970385L NO 970385 L NO970385 L NO 970385L NO 970385 A NO970385 A NO 970385A NO 970385 A NO970385 A NO 970385A NO 970385 L NO970385 L NO 970385L
Authority
NO
Norway
Prior art keywords
bch
preparation
therapeutically active
analogous process
active nucleoside
Prior art date
Application number
NO970385A
Other languages
English (en)
Other versions
NO970385D0 (no
NO324979B1 (no
Inventor
Dennis C Liotta
Woo-Baeg Choi
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23879071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO970385(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO970385L publication Critical patent/NO970385L/no
Application filed by Univ Emory filed Critical Univ Emory
Publication of NO970385D0 publication Critical patent/NO970385D0/no
Publication of NO324979B1 publication Critical patent/NO324979B1/no
Priority to NO20083728A priority Critical patent/NO20083728L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
NO19970385A 1990-02-01 1997-01-29 Analogifremgangsmate for fremstilling av et terapeutisk aktivt nukleosid NO324979B1 (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20083728A NO20083728L (no) 1990-02-01 2008-08-28 Analogifremgangsmate for fremstilling av et terapeutisk aktivt nukleosid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/473,318 US5204466A (en) 1990-02-01 1990-02-01 Method and compositions for the synthesis of bch-189 and related compounds
PCT/US1991/000685 WO1991011186A1 (en) 1990-02-01 1991-01-31 Method and compositions for the synthesis of bch-189 and related compounds

Publications (3)

Publication Number Publication Date
NO970385L true NO970385L (no) 1992-07-30
NO970385D0 NO970385D0 (no) 1997-01-29
NO324979B1 NO324979B1 (no) 2008-01-14

Family

ID=23879071

Family Applications (6)

Application Number Title Priority Date Filing Date
NO923014A NO923014D0 (no) 1990-02-01 1992-07-30 Fremgangsmaate og preparat for syntese av bch-189 og relaterte forbindelser
NO19970386A NO313048B1 (no) 1990-02-01 1997-01-29 Fremgangsmåte for fremstilling av et terapeutisk aktivt racemisk cis-1,3-oksatiolan
NO19970385A NO324979B1 (no) 1990-02-01 1997-01-29 Analogifremgangsmate for fremstilling av et terapeutisk aktivt nukleosid
NO20065640A NO326249B1 (no) 1990-02-01 2006-12-07 Fremgangsmate for fremstilling av en nukleosidsammensetning omfattende et 2`,3`-dideoksy-3`-tiapyrimidinnukleosid, mellomprodukter for anvendelse i fremgangsmaten samt fremgangsmate for fremstilling av mellomprodukt
NO2008011C NO2008011I2 (no) 1990-02-01 2008-07-11 Emtricitabin (5-fluor-1-(2R,5S)-[2-(hydroksymetyl)-1,3-oksotiolan-5-y]ytosin
NO20083728A NO20083728L (no) 1990-02-01 2008-08-28 Analogifremgangsmate for fremstilling av et terapeutisk aktivt nukleosid

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO923014A NO923014D0 (no) 1990-02-01 1992-07-30 Fremgangsmaate og preparat for syntese av bch-189 og relaterte forbindelser
NO19970386A NO313048B1 (no) 1990-02-01 1997-01-29 Fremgangsmåte for fremstilling av et terapeutisk aktivt racemisk cis-1,3-oksatiolan

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO20065640A NO326249B1 (no) 1990-02-01 2006-12-07 Fremgangsmate for fremstilling av en nukleosidsammensetning omfattende et 2`,3`-dideoksy-3`-tiapyrimidinnukleosid, mellomprodukter for anvendelse i fremgangsmaten samt fremgangsmate for fremstilling av mellomprodukt
NO2008011C NO2008011I2 (no) 1990-02-01 2008-07-11 Emtricitabin (5-fluor-1-(2R,5S)-[2-(hydroksymetyl)-1,3-oksotiolan-5-y]ytosin
NO20083728A NO20083728L (no) 1990-02-01 2008-08-28 Analogifremgangsmate for fremstilling av et terapeutisk aktivt nukleosid

Country Status (21)

Country Link
US (8) US5204466A (no)
EP (3) EP0513200B2 (no)
JP (6) JPH07618B2 (no)
KR (2) KR100188357B1 (no)
AT (1) ATE170750T1 (no)
AU (6) AU658136C (no)
BG (1) BG62236B1 (no)
CA (3) CA2678778A1 (no)
DE (4) DE69130166T3 (no)
DK (2) DK0513200T4 (no)
ES (2) ES2076130T5 (no)
FI (4) FI114471B (no)
GR (1) GR950300024T1 (no)
HU (4) HU9202496D0 (no)
LU (1) LU91073I2 (no)
MC (1) MC2233A1 (no)
NL (1) NL300148I2 (no)
NO (6) NO923014D0 (no)
RO (1) RO108564B1 (no)
RU (1) RU2125558C1 (no)
WO (1) WO1991011186A1 (no)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6175008B1 (en) * 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en) * 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
HU226137B1 (en) * 1989-02-08 2008-05-28 Shire Canada Inc Process for preparing substituted 1,3-oxathiolanes with antiviral properties
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US20090239887A1 (en) * 1990-02-01 2009-09-24 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
RU2116789C1 (ru) * 1991-03-06 1998-08-10 Дзе Велкам Фаундейшн Лимитед Способ ингибирования вирусных инфекций гепатита в
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6689761B1 (en) 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9506644D0 (en) * 1995-03-31 1995-05-24 Wellcome Found Preparation of nucleoside analogues
DE19514523A1 (de) * 1995-04-12 1996-10-17 Schering Ag Neue Cytosin- und Cytidinderivate
DK0831852T3 (da) * 1995-06-07 2007-03-19 Univ Emory Nukleosider med anti-hepatitis B-virusaktivitet
JP2000515852A (ja) 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
DE69823984T2 (de) 1997-03-19 2005-05-12 University Of Georgia Research Foundation, Inc. Synthese, anti-hiv- und anti-hepatitis-b-virus-aktivitäten von 1,3-oxaselenolannukleosiden
JP2001518899A (ja) 1997-04-07 2001-10-16 トライアングル ファーマシューティカルズ，インコーポレイティド 他の抗ウイルス剤との組合せにおけるｍｋｃ−４４２の使用
AU2787199A (en) 1998-02-25 1999-09-15 Emory University 2'-fluoronucleosides
EP1754710A3 (en) 1998-02-25 2007-12-19 Emory University 2'-Fluoroncucleosides
ATE313550T1 (de) 1998-08-10 2006-01-15 Idenix Cayman Ltd Beta-l-2'-deoxynukleoside für die behandlung von hepatitis b virus
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
EP1104415B1 (en) * 1998-08-12 2004-11-10 Gilead Sciences, Inc. Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en) * 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
ES2237189T3 (es) 1998-11-02 2005-07-16 Gilead Sciences, Inc. Terapia de combinacion para tratar virus de la hepatitis b.
EP1124839B1 (en) 1998-11-05 2006-01-11 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis b virus activity
RU2237479C2 (ru) * 1998-11-05 2004-10-10 Сантр Насьональ Де Ля Решерш Сьентифик Нуклеозиды, обладающие активностью против вируса гепатита в
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
EA004767B1 (ru) 1998-12-23 2004-08-26 Шайре Байокем Инк. Аналоги нуклеозида (варианты) и их применение, комбинация и способ лечения вирусных инфекций, фармацевтическая композиция
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
EP1600452A3 (en) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
KR100789162B1 (ko) * 1999-11-12 2007-12-28 파마셋 인코포레이티드 2'-데옥시-ｌ-뉴클레오사이드의 합성
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP5230052B2 (ja) * 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CN1446225A (zh) * 2000-08-09 2003-10-01 可隆株式会社 5′－脱氧－n－(取代氧羰基)－5－氟胞嘧啶及其衍生物、制备方法,和包括该物质作为活性成分的抗癌组合物
US20030166606A1 (en) * 2000-08-09 2003-09-04 Kwan-Hee Kim 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
ATE491459T1 (de) 2000-10-18 2011-01-15 Pharmasset Inc Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation
DE10104231A1 (de) 2001-01-31 2002-08-08 Consortium Elektrochem Ind Verfahren zur enzymatischen Herstellung von enantiomerenreinen 1,3-Dioxolan-4-on-Derivaten
CN1503796B (zh) 2001-03-01 2012-07-04 三角药品公司 顺-ftc的多晶型物及其它晶型
CA2380804A1 (en) * 2001-05-01 2002-11-01 Mitsui Chemicals, Inc. Method for producing cytosine nucleosides compounds
US6600044B2 (en) 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
ITMI20012317A1 (it) * 2001-11-06 2003-05-06 Recordati Ind Chimica E Farma Processo diastereoselettivo per la preparazione del'agente antivirale4-amino-1-(2r-idrossimetil-/1,3/ossatiolan-5s-i1)-1h-pirimidin-2-one
US20030162992A1 (en) * 2001-12-14 2003-08-28 Watanabe Kyoichi A. Preparation of intermediates useful in the synthesis of antiviral nucleosides
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
AU2003234737B2 (en) * 2002-04-12 2009-08-27 Achillion Pharmaceuticals, Inc. Method for synthesizing Beta-L-fluoro-2',3'didehydrocytidine (Beta-L-FD4C)
AP2005003213A0 (en) * 2002-06-28 2005-03-31 Univ Cagliari 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
EP1534255B1 (en) 2002-08-06 2011-01-19 Pharmasset, Inc. Processes for preparing 1,3-dioxolane nucleosides
DK1572095T3 (en) * 2002-09-13 2015-09-14 Novartis Ag BETA-L-2'-DEOXYNUCLEOTIDES FOR TREATMENT OF RESISTANT HBV STANDS AND COMBINATION THERAPIES
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
CA2502625A1 (en) * 2002-12-09 2004-06-24 The University Of Georgia Research Foundation, Inc. Dioxolane thymine and combinations for use against resistant strains of hiv
MXPA05006230A (es) * 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
SI1583542T1 (sl) * 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
EP1639121A4 (en) * 2003-06-30 2008-04-16 Idenix Cayman Ltd SYNTHESIS OF BETA-L-2-DESOXYNUCLEOSIDES
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
PL1692516T3 (pl) * 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
WO2005074654A2 (en) * 2004-02-03 2005-08-18 Emory University Methods to manufacture 1,3-dioxolane nucleosides
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
JP4058057B2 (ja) * 2005-04-26 2008-03-05 株式会社東芝 日中機械翻訳装置、日中機械翻訳方法および日中機械翻訳プログラム
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
BRPI0617720A2 (pt) 2005-10-19 2011-08-02 Hoffmann La Roche compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
ES2422290T3 (es) * 2005-12-23 2013-09-10 Idenix Pharmaceuticals Inc Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
ATE461208T1 (de) * 2006-01-17 2010-04-15 Organon Nv Selektive enzymatische hydrolyse von c-terminalen tert-butyl-peptidestern
US9044509B2 (en) * 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
US8895531B2 (en) * 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
CA2649796A1 (en) * 2006-04-18 2007-10-25 Lupin Limited A novel crystalline form of lamivudine
PT2049506E (pt) 2006-07-07 2015-10-09 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
AU2007332654B2 (en) 2006-12-13 2013-06-20 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
BRPI0807581A2 (pt) 2007-02-23 2014-07-01 Gilead Science, Inc. Moduladores de propriedades farmacocinéticas de produtos terapêuticos
CN101307048B (zh) * 2007-05-18 2011-03-23 上海迪赛诺医药发展有限公司 立体选择性制备拉米夫定的方法
USRE45004E1 (en) 2007-06-18 2014-07-08 Sunshine Lake Pharma Co., Ltd. Bromo-phenyl substituted thiazolyl dihydropyrimidines
US9296776B2 (en) 2007-07-09 2016-03-29 Eastern Virginia Medical School Substituted nucleoside derivatives with antiviral and antimicrobial properties
RU2373218C2 (ru) * 2007-08-10 2009-11-20 Роберт Шалвович Бибилашвили 5'-фосфорсодержащие производные 2',3'-дидезокси-3'-тиацитидина новые противовирусные агенты
WO2009052050A1 (en) * 2007-10-15 2009-04-23 Pharmasset, Inc. Dioxolane thymine phosphoramidates as anti-hiv agents
SI2225232T1 (sl) * 2007-11-29 2012-12-31 Ranbaxy Laboratories Limited Postopek za pripravo substituiranih 1,3-oksatiolanov
BRPI0820224A2 (pt) * 2007-11-29 2015-06-16 Ranbaxy Lab Ltd Composto de fórmula iii ou seus estereoisômeros; processo para sua preparação e seu uso; uso de um composto de formula iii(a) ou iii(b) em um processo para a preparação de lamivudina de fórmula i(a) ou um composto de fórmula i(c); processo para preparação de lamivudina de fórmula i(a)
JPWO2009107692A1 (ja) 2008-02-29 2011-07-07 株式会社カネカ ２’−水酸基が保護されたリボヌクレオシド誘導体およびその製造方法
US20110288298A1 (en) * 2008-11-12 2011-11-24 Lupin Limited novel polymorph of emtricitabine and a process for preparing of the same
WO2010077613A1 (en) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
WO2010082128A1 (en) 2009-01-19 2010-07-22 Aurobindo Pharma Limited Process for the preparation of cis-nucleoside derivative
KR101474570B1 (ko) 2009-04-13 2014-12-19 주식회사 대희화학 라미부딘의 신규한 중간체 및 이의 제조방법
HUE026456T2 (en) 2009-05-27 2016-05-30 Biotempus Ltd Methods of treating diseases
US8710218B2 (en) 2009-07-15 2014-04-29 Lupin Limited Process for preparation of Efavirenz
US20120295930A1 (en) 2010-02-03 2012-11-22 Shankar Rama Novel process for the preparation of cis-nucleoside derivative
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
WO2011141805A2 (en) 2010-05-14 2011-11-17 Lupin Limited An improved process for the manufacture of lamivudine
EP2739620A1 (en) 2011-08-05 2014-06-11 Lupin Limited A stereoselective process for preparation of 1,3-oxathiolane nucleosides
CN102584800A (zh) * 2011-12-16 2012-07-18 四川大学 手性吲哚酮和当归内酯骨架化合物及不对称合成
EP2846788A1 (en) 2012-05-11 2015-03-18 Akron Molecules AG Use of compounds for the treatment of pain
ES2725491T3 (es) * 2012-11-16 2019-09-24 Univ College Cardiff Consultants Ltd Mezcla de RP/SP gemcitabina-[fenil-(benciloxi-L-alaninil)]-fosfato
SI2822954T1 (sl) 2012-12-21 2016-07-29 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
NO2865735T3 (no) 2013-07-12 2018-07-21
PT3019503T (pt) 2013-07-12 2017-11-27 Gilead Sciences Inc Compostos carbamoílpiridona- policíclicos e seu uso para o tratamento de infecções por hiv
MX2016002560A (es) 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (no) 2014-06-20 2018-06-23
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
EP4140485A1 (en) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016161382A1 (en) 2015-04-02 2016-10-06 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
HK1257270A1 (zh) 2015-09-15 2019-10-18 Gilead Sciences, Inc. 用於治療hiv的toll樣受體(tlr)調節劑
GB201610327D0 (en) * 2016-06-14 2016-07-27 Univ Nelson Mandela Metropolitan Process for producing Lamivudine and Entricitabine
EP3601301A1 (en) 2017-03-31 2020-02-05 The University of Liverpool Prodrug compositions
CA3087932A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5259171A (en) * 1975-11-10 1977-05-16 Asahi Chem Ind Co Ltd Preparation of uracil derivatives
JPS6045196B2 (ja) * 1976-08-09 1985-10-08 株式会社興人 １−（２−テトラヒドロフリル）ウラシル類の製造方法
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
JPS5738774A (en) * 1980-08-19 1982-03-03 Chugai Pharmaceut Co Ltd Uracil derivative and its preparation
JPS5839672A (ja) * 1981-09-03 1983-03-08 Chugai Pharmaceut Co Ltd ウラシル誘導体
EP0151189B1 (en) * 1983-07-20 1990-01-31 Teijin Limited Antineoplastic agent
DE3534979A1 (de) * 1985-07-25 1987-01-29 Licentia Gmbh Netzgeraet
AU570853B2 (en) * 1985-08-26 1988-03-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Inhibition of infectivity and cytopathic effect of htlv-111/ lav by purine bases
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
GB2181128A (en) * 1985-09-17 1987-04-15 Wellcome Found 3'-azidonucleosides
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
WO1988007532A1 (en) * 1987-03-24 1988-10-06 Nycomed A.S. 2',3' dideoxyribofuranoxide derivatives
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5011774A (en) * 1987-07-17 1991-04-30 Bristol-Myers Squibb Co. Dideoxyinosine by enzymatic deamination of dideoxyadenosine
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US6175008B1 (en) * 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
CA1318627C (en) * 1988-07-14 1993-06-01 Jeffrey M. Howell Enzymatic resolution process
US5106750A (en) * 1988-08-30 1992-04-21 G. D. Searle & Co. Enantio- and regioselective synthesis of organic compounds using enol esters as irreversible transacylation reagents
JPH0269469A (ja) * 1988-09-06 1990-03-08 Kohjin Co Ltd ジヒドロフラン誘導体及びその製法
JPH0269476A (ja) * 1988-09-06 1990-03-08 Kohjin Co Ltd ピリミジン誘導体の製法
GB8822546D0 (en) * 1988-09-26 1988-11-02 Wellcome Found Antiviral combinations
AU618436B2 (en) * 1988-12-19 1991-12-19 Wellcome Foundation Limited, The Antiviral cytosine and guanine derivatives
HU226137B1 (en) * 1989-02-08 2008-05-28 Shire Canada Inc Process for preparing substituted 1,3-oxathiolanes with antiviral properties
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
CA2023856A1 (en) * 1989-09-26 1991-03-27 Jeffrey M. Howell Enzymatic resolution process
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
IT1246983B (it) * 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
RU2116789C1 (ru) * 1991-03-06 1998-08-10 Дзе Велкам Фаундейшн Лимитед Способ ингибирования вирусных инфекций гепатита в
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9307013D0 (en) * 1993-04-02 1993-05-26 Wellcome Found Therapeutic combinations
SE510803C2 (sv) * 1994-12-13 1999-06-28 Volvo Ab Tryckmediepåverkad manöveranordning
US5639787A (en) * 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer

Also Published As

Publication number Publication date
NL300148I1 (nl) 2004-07-01
DE513200T1 (de) 1995-07-13
EP0513200B1 (en) 1998-09-09
AU2002300661B2 (en) 2006-06-08
CA2481078C (en) 2009-12-15
HUT62566A (en) 1993-05-28
NL300148I2 (nl) 2004-11-01
NO923014L (no) 1992-07-30
FI121069B (fi) 2010-06-30
BG62236B1 (bg) 1999-06-30
WO1991011186A1 (en) 1991-08-08
CA2075189A1 (en) 1991-08-02
JPH05505794A (ja) 1993-08-26
AU7300491A (en) 1991-08-21
NO970386D0 (no) 1997-01-29
DE122004000015I1 (de) 2004-08-12
AU698859B2 (en) 1998-11-12
KR100381705B1 (ko) 2003-04-26
DE69133556D1 (de) 2007-03-08
KR100188357B1 (ko) 1999-06-01
AU4031995A (en) 1996-04-26
EP0513200B2 (en) 2004-04-28
EP0872237A1 (en) 1998-10-21
JP4108645B2 (ja) 2008-06-25
MC2233A1 (fr) 1993-02-23
JP2006141408A (ja) 2006-06-08
ES2076130T5 (es) 2004-12-16
NO2008011I1 (no) 2008-07-28
FI114471B (fi) 2004-10-29
HU227485B1 (en) 2011-07-28
ES2279559T3 (es) 2007-08-16
JP2002012591A (ja) 2002-01-15
EP0513200A1 (en) 1992-11-19
HK1014664A1 (en) 1999-09-30
JP3530150B2 (ja) 2004-05-24
DK0513200T3 (da) 1999-05-25
FI20050672L (fi) 2005-06-22
JP2005053893A (ja) 2005-03-03
NO2008011I2 (no) 2010-10-18
FI923446L (fi) 1992-07-30
JP2001352997A (ja) 2001-12-25
JP4496377B2 (ja) 2010-07-07
NO970385D0 (no) 1997-01-29
EP1772151A3 (en) 2007-06-13
DE69130166T2 (de) 1999-04-08
US5814639A (en) 1998-09-29
US5210085A (en) 1993-05-11
US5539116A (en) 1996-07-23
NO326249B1 (no) 2008-10-27
DE69130166T3 (de) 2005-04-14
DE69133556T2 (de) 2007-08-16
CA2678778A1 (en) 1991-08-08
AU2006207874A1 (en) 2006-09-28
FI20060622A7 (fi) 2006-06-27
EP0872237B1 (en) 2007-01-17
US5204466A (en) 1993-04-20
US6153751A (en) 2000-11-28
NO923014D0 (no) 1992-07-30
JP2001019690A (ja) 2001-01-23
AU658136B2 (en) 1995-04-06
RU2125558C1 (ru) 1999-01-27
BG96717A (bg) 1993-12-24
ES2076130T3 (es) 1999-03-01
LU91073I2 (fr) 2004-04-23
NO20065640L (no) 1992-07-30
AU698859C (en) 2003-01-30
DK0872237T3 (da) 2007-04-23
HU211300A9 (en) 1995-11-28
DE122004000015I2 (de) 2004-11-18
CA2481078A1 (en) 1991-08-08
AU2010201878A1 (en) 2010-05-27
ATE170750T1 (de) 1998-09-15
EP0513200A4 (en) 1993-04-07
US20050004148A1 (en) 2005-01-06
ES2076130T1 (es) 1995-11-01
NO970386L (no) 1992-07-30
FI923446A0 (fi) 1992-07-30
KR920703582A (ko) 1992-12-18
JPH07618B2 (ja) 1995-01-11
FI20030933A7 (fi) 2003-06-24
FI116222B (fi) 2005-10-14
CA2075189C (en) 2004-11-30
JP3844978B2 (ja) 2006-11-15
GR950300024T1 (en) 1995-06-30
FI20060622L (fi) 2006-06-27
AU658136C (en) 2003-06-12
NO20083728L (no) 1992-07-30
DK0513200T4 (da) 2004-07-05
HU9202496D0 (en) 1992-12-28
AU2006207874B2 (en) 2010-02-11
NO313048B1 (no) 2002-08-05
AU4474599A (en) 1999-11-11
RO108564B1 (ro) 1994-06-30
NO324979B1 (no) 2008-01-14
EP1772151A2 (en) 2007-04-11
US6114343A (en) 2000-09-05
DE69130166D1 (de) 1998-10-15
US5914400A (en) 1999-06-22

Similar Documents

Publication Publication Date Title
NO20065640L (no) Analogifremgangsmate for fremstilling av et terapeutisk aktivt nukleosid
ATE214707T1 (de) 5-halo-5-deoxy-sorbopyranose-verbindungen
EG19958A (en) Process for preparing of 1.3 oxathiolane nucleoside analogues
HUT64310A (en) Compositions containing substituted aryl-halogenalkyl-pyrazol derivatives having herbicidal activity and process for producing said compounds
FI885153A0 (fi) Menetelmä terapeuttisesti aktiivisten 2',3'-dideoksi-2'-fluorinukleosidien valmistamiseksi
DE69227490D1 (de) Verfahren zur Herstellung aktiver Kohlenstoffasern
RU92016627A (ru) Способ и составы для синтеза всн-189 и родственных соединений
NO177710C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive slektede analoger

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: EMTRIVA; NAT. REG. NO/DATE: EU103261001NO/002NO 20031024; FIRST REG. NO/DATE: EU , EU103261001-003 20031024

Spc suppl protection certif: 2008011

Filing date: 20080711

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: EMTRIVA; NAT. REG. NO/DATE: EU103261001NO/002NO 20031024; FIRST REG. NO/DATE: EU , EU103261001-003 20031024

Spc suppl protection certif: 2008011

Filing date: 20080711

Extension date: 20160131

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2008011